Aptamer Sciences has made our efforts to develop technologies which effectively discover high quality aptamers, technologies which optimize the discovered aptamers to serve the purpose of application, and to build the technology platform with a distinctive aptamer archive.

Aptamer Discovery Technology
SELEX is a combinatorial technique for discovering aptamers which bind to target molecules with high affinity and specificity; briefly, combining target molecules with nucleic acid libraries with diversity, removing unbound nucleic acids, and collecting the remaining nucleic acids which bind to targets.
PCR amplification and repeating above process make it possible to enrich the only nucleic acids with high affinity to target molecules. The final aptamer clones are selected by sequencing and analyzing their affinity to a target. Since SELEX was firstly developed by Professor Larry Gold at the University of Colorado in 1990, a number of aptamers against a variety of target molecules have been discovered.

Aptamer Optimization Technology
Selected aptamers will go through the optimization process to increase their utility for application. This technology is essential in terms of developing therapeutics and early-stage diagnostic products. Aptamer Sciences is striving to optimize aptamers to have their best structures and efficacy by allowing them to go through “truncation,” “lead optimization,” “ligand scan,” and “aptamer pair discovery”.

Aptamer Archive
Aptamer Sciences has an archive of selective and high-affinity aptamers for more than 250 membrane receptor proteins which are valid for therapeutic targets. Drug candidates for the development of innovative aptamer-based therapeutics are identified and selected through the optimization process.